Clinical Trial Update: MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes [Phase 1]

View source ↗

Summary

A Phase 1 study of MER3101 (MAS-1 adjuvanted antigen-specific immunotherapeutic) for Type 1 Diabetes Mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• MER3101 MAS-1 Adjuvanted Antigen-specific Immunotherapeutic (MAS-1 Adjuvanted Antigen-specific Immunotherapeutic)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED